Kadcyla is a targeted biologic medicine containing Ado-Trastuzumab Emtansine, used in the treatment of certain HER2-positive breast cancers. It combines targeted therapy with chemotherapy to specifically attack cancer cells and help slow disease progression.
Indications
-
Treatment of HER2-positive breast cancer
-
Used in advanced or metastatic disease
-
Used when previous treatments are not effective
-
Helps reduce cancer cell growth and spread
Directions for Use
Administered by intravenous infusion in a hospital or clinical setting under specialist supervision.
Warnings
-
Prescription medicine – use under medical supervision
-
May affect liver or heart function
-
May cause low blood cell counts or fatigue
-
Regular medical monitoring is required
-
Not recommended during pregnancy
-
Keep out of reach of children
Reviews
There are no reviews yet.